Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lagricel Ofteno is an ophthalmic solution containing sodium hyaluronate (a derivative of hyaluronic acid) as its active ingredient. It is primarily used as an eye lubricant for the treatment and relief of dry eye symptoms and ocular surface irritation. Sodium hyaluronate acts by mimicking natural tears, providing lubrication and moisture to the ocular surface, promoting corneal healing after procedures such as photorefractive keratectomy (PRK), and improving comfort in patients with dry eye disease. The mechanism of action involves enhancing tear film stability and protecting epithelial cells on the ocular surface through its viscoelastic properties[1][3][7]. Clinical studies have evaluated both single-dose and multi-dose formulations for safety, tolerability, and efficacy in conditions like dry eye disease and post-PRK recovery[3][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lagricel ofteno.